Brazilian registry of people with hemophilia A using emicizumab (Emicizumab Cases, EMCase)

niversidade Federal de Minas Gerais0 个研究点开始时间: 2020年3月23日最近更新: 2023年5月29日

研究概览

暂无简介。

•Any patient with AH who is going to use or is using MC-Ab may be included in the study, by clarifying and signing the appropriate terms (Free and Informed Consent Form / TALE, for children between 6 and 17 years old; and Term of Free and Informed Consent / ICF, for caregivers responsible for children up to 17 years of age and for patients aged 18 or over), according to Resolution 466, of December 12, 2012, of the National Health Council. service in which the patient is treated must be regularly and ethically registered in the registry, according to the norm of each institution.As patients using the MC-Ab appear, services will be registered through amendments and patients will be included, after signing the appropriate terms (TCLE / TALE). The study will remain open for the capture of new cases for 12 years and each patient will be followed for up to 10 years. The evaluated indicators will be collected at the frequency of each institution, based on the guidelines of the coordinating team. Attention will be paid so that there is at least one evaluation of each indicator before starting to use the MC-Ab.

发起方

niversidade Federal de Minas Gerais